Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIH study of Lu AF90103 in healthy men
NCT04940949Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AF90103 in major depressive disorder (MDD) (3 arms), sponsored by Lundbeck. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Maximum Observed Concentration (Cmax) of Lu AF90103 and AF88361 in Plasma and Cerebrospinal Fluid (CSF) and 4 more. Started May 2021; status: terminated.
02
Drugs
Lu AF90103
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04940949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940949.